Clinical trial
Dosing and Safety Study of E7820 in Patients With a Malignant Solid Tumor or…
NCT00078637 · Eisai Inc., Industry · Completed
Key facts
| NCT number | NCT00078637 |
|---|---|
| Title | Dosing and Safety Study of E7820 in Patients With a Malignant Solid Tumor or Lymphoma |
| Official title | Phase I and Pharmacokinetic Study of E7820 After Oral Administration to Patients With Malignancy |
| Lead sponsor | Eisai Inc., Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Neoplasms, Lymphoma, Malignant |
| Intervention type | Drug |
| Interventions | E7820 |
| Enrollment | 37 |
| Start date | Jan 1, 2004 |
| Primary completion | Aug 1, 2006 |
| Completion | Feb 1, 2007 |
| First posted | Mar 5, 2004 |
| Last update posted | Dec 23, 2014 |
| Countries | United States |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: